Universal Beteiligungs und Servicegesellschaft mbH bought a new position in CorVel Corp. (NASDAQ:CRVL - Free Report) in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 8,361 shares of the business services provider's stock, valued at approximately $936,000.
Several other hedge funds have also modified their holdings of the stock. American Century Companies Inc. boosted its holdings in CorVel by 200.8% in the fourth quarter. American Century Companies Inc. now owns 13,832 shares of the business services provider's stock worth $1,539,000 after purchasing an additional 9,233 shares during the period. LPL Financial LLC boosted its position in CorVel by 183.3% during the 4th quarter. LPL Financial LLC now owns 10,807 shares of the business services provider's stock valued at $1,202,000 after purchasing an additional 6,992 shares during the period. JPMorgan Chase & Co. grew its stake in CorVel by 363.4% during the 4th quarter. JPMorgan Chase & Co. now owns 176,631 shares of the business services provider's stock worth $19,652,000 after buying an additional 138,518 shares during the last quarter. Norges Bank acquired a new stake in CorVel in the fourth quarter worth $41,393,000. Finally, Pictet Asset Management Holding SA lifted its position in CorVel by 264.0% in the 4th quarter. Pictet Asset Management Holding SA now owns 4,095 shares of the business services provider's stock valued at $456,000 after purchasing an additional 2,970 shares during the last quarter. 51.36% of the stock is currently owned by hedge funds and other institutional investors.
CorVel Price Performance
Shares of CorVel stock traded up $1.40 on Tuesday, hitting $87.92. The company had a trading volume of 68,930 shares, compared to its average volume of 132,440. CorVel Corp. has a 52 week low of $86.14 and a 52 week high of $128.61. The company has a market cap of $4.52 billion, a PE ratio of 47.86 and a beta of 0.95. The business has a 50-day simple moving average of $100.88 and a 200-day simple moving average of $108.30.
CorVel (NASDAQ:CRVL - Get Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The business services provider reported $0.52 EPS for the quarter. CorVel had a return on equity of 32.55% and a net margin of 10.63%.
Wall Street Analysts Forecast Growth
Separately, Wall Street Zen upgraded CorVel from a "hold" rating to a "buy" rating in a research report on Friday, April 18th.
Get Our Latest Report on CRVL
Insider Activity at CorVel
In other news, CFO Brandon O'brien sold 3,957 shares of the stock in a transaction on Monday, June 9th. The stock was sold at an average price of $108.46, for a total transaction of $429,176.22. Following the completion of the sale, the chief financial officer owned 11,804 shares in the company, valued at approximately $1,280,261.84. This represents a 25.11% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Jennifer Yoss sold 1,050 shares of CorVel stock in a transaction on Thursday, May 29th. The stock was sold at an average price of $111.39, for a total value of $116,959.50. Following the completion of the transaction, the vice president owned 2,088 shares in the company, valued at $232,582.32. The trade was a 33.46% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 13,079 shares of company stock worth $1,446,023. Company insiders own 44.56% of the company's stock.
CorVel Profile
(
Free Report)
CorVel Corporation provides workers' compensation, auto, liability, and health solutions. It applies technology, including artificial intelligence, machine learning, and natural language processing to enhance the managing of episodes of care and the related health care costs. The company also offers network solutions services, including automated medical fee auditing, preferred provider management and reimbursement, retrospective utilization review, facility claim review, professional review, pharmacy, directed care, clearinghouse, independent medical examination, and inpatient medical bill review services, as well as Medicare solutions.
Featured Stories

Before you consider CorVel, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CorVel wasn't on the list.
While CorVel currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.